MIAMI, July 6 /PRNewswire-FirstCall/ -- Orthodontix announced today that it has appointed Dr. Curtis Lockshin to fill one of the vacancies on its Board of Directors.
“Curt Lockshin brings over 12 years of pharmaceutical experience and leadership skills to this role,” said Glenn Halpryn, Chairman and Director of Orthodontix Inc. “We are delighted to welcome Dr. Lockshin to Orthodontix’s Board of Directors, and we look forward to benefiting from his substantial experience.”
Dr. Lockshin is a consultant with expertise across all areas of drug discovery and development; his consulting activity is presently focused on small companies that seek to leverage their technology assets inside healthcare, biotechnology, and security sectors. While at Sepracor Inc., Dr. Lockshin was instrumental in establishing the company’s New Leads program, which delivered novel chemical entities into the preclinical pipeline. At Beyond Genomics, Inc., he co-developed strategies for utilizing the company’s technology platforms in clinical trial optimization and prediction of off-target drug activities. Dr. Lockshin is a co-inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. He holds a Bachelor’s degree in Life Sciences and a PhD in Biological Chemistry, both from MIT.
This appointment brings the number of directors on the Orthodontix Board to four.
Orthodontix
CONTACT: Glenn Halpryn, Chairman and Director of Orthodontix,+1-305-371-4112
